NanoBio to Report Data on its Nanoemulsion Adjuvanted Intranasal RSV Vaccine at the 8th Annual International Respiratory Syncytial Virus Symposium
ANN ARBOR, Mich. & SANTA FE, N.M.--(BUSINESS WIRE)--Sep 24, 2012 - NanoBio® Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
The following presentations will occur on Friday, Sept. 28 at 9:30 - 10:30 a.m. Mountain Time:
Poster Presentation 51: “Whole virus RSV vaccine induced protective immunity with reduced lung histopathology compared to recombinant F protein RSV vaccine.”
Poster Presentation 49: “Intranasal and Intramuscular Routes of RSV Vaccine Administration Serve to Highlight the Role of Th2 and Th17 in a Mouse RSV Challenge Model.”
Poster Presentation 45: “Immunogenicity and efficacy of Line 19 RSV vaccine in cotton rats.”
During the presentations, NanoBio will share preclinical data on its nanoemulsion adjuvanted intranasal RSV vaccine which:
- Demonstrated improved viral clearance and reduced histopathology in an RSV mouse challenge model.
- Resulted in viral clearance from the lung associated with Th17 generation that is highly correlated with lower airway hyper-reactivity (AHR).
- Generated robust immune responses that are protective against a heterologous A2 challenge in cotton rats.
NanoBio's RSV vaccine uses nanoemulsion technology as an intranasal adjuvant and delivery system derived from its clinically-validated NanoStat® technology platform.
RSV is a highly contagious viral disease and is one of the most common causes of bronchiolitis and pneumonia. It is the number one cause of childhood hospitalization both in the United States and around the world. Nearly all children are infected with the virus at least once by the age of 2-3 years. The disease is particularly dangerous for premature babies, children with other health conditions and the elderly. Many children develop pulmonary disease and/or asthma from RSV that persists throughout adult life making them susceptible to re-infection. Currently, there are no approved vaccines for RSV, despite tremendous need and widespread interest to develop new therapies.
NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat® technology platform. The company's lead product candidates are treatments for herpes labialis, onychomycosis, vaginitis, cystic fibrosis and a broad platform of intranasal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.
Contact: Schwartz MSL
Benjamin Navon, 781-684-0770
Posted: September 2012